title: Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
abstract: The aim of this study was to evaluate the oncologic and pregnancy outcomes of combined oral medroxyprogesterone acetate (MPA)/levonorgestrel-intrauterine system (LNG-IUS) treatment in young women with grade 2-differentiated stage IA endometrial adenocarcinoma who wish to preserve fertility.
  
  
  
  We retrospectively reviewed the medical records of patients with grade 2 stage IA endometrial adenocarcinoma who had received fertility-sparing treatment at CHA Gangnam Medical Center between 2011 and 2015. All of the patients were treated with combined oral MPA (500 mg/d)/LNG-IUS, and follow-up dilatation and curettage were performed every 3 months.
  
  
  
  A total of 5 patients were included in the study. The mean age was 30.4 ± 5.3 years (range, 25-39 years). After a mean treatment duration of 11.0 ± 6.2 months (range, 6-18 months), complete response (CR) was shown in 3 of the 5 patients, with partial response (PR) in the other 2 patients. One case of recurrence was reported 14 months after achieving CR. This patient was treated again with combined oral MPA/LNG-IUS and achieved CR by 6 months. The average follow-up period was 44.4 ± 26.2 months (range, 12-71 months). There were no cases of progressive disease. No treatment-related complications arose.
  
  
  
  Combined oral MPA/LNG-IUS treatment is considered to be a reasonably effective fertility-sparing treatment of grade 2 stage IA endometrial cancer. Although our results are encouraging, it is preliminary and should be considered with experienced oncologists in well-defined protocol and with close follow-up.
authors.affiliation: Departments of *Obstetrics and Gynecology and †Pathology CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea.
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Hwang
authors.forename: Da Hee
authors.initials: DH
authors.lastname: Kim
authors.forename: Hyo Sook
authors.initials: HS
authors.lastname: Bae
authors.forename: Mi-La
authors.initials: ML
authors.lastname: Kim
authors.forename: Yong Wook
authors.initials: YW
authors.lastname: Jung
authors.forename: Bo Seong
authors.initials: BS
authors.lastname: Yun
authors.forename: Seok Ju
authors.initials: SJ
authors.lastname: Seong
authors.forename: Eunah
authors.initials: E
authors.lastname: Shin
authors.forename: Mi Kyoung
authors.initials: MK
authors.lastname: Kim
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000473:pathology; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D059247:Fertility Preservation; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage*; D008525:Medroxyprogesterone / Q000008:administration & dosage*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies
chemical_list: D016912:Levonorgestrel; D008525:Medroxyprogesterone